[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 997,347
  • Shares Outstanding, K 39,862
  • Annual Sales, $ 726,410 K
  • Annual Income, $ 7,030 K
  • EBIT $ 81 M
  • EBITDA $ 170 M
  • 60-Month Beta 0.27
  • Price/Sales 1.40
  • Price/Cash Flow 6.63
  • Price/Book 1.50

Options Overview Details

View History
  • Implied Volatility 57.97% (+1.39%)
  • Historical Volatility 39.40%
  • IV Percentile 28%
  • IV Rank 21.07%
  • IV High 128.93% on 03/16/26
  • IV Low 39.03% on 08/20/25
  • Expected Move (DTE 12) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 22
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 1,272
  • Open Int (30-Day) 1,154
  • Expected Range 25.02 to 25.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.48
  • Number of Estimates 1
  • High Estimate $0.48
  • Low Estimate $0.48
  • Prior Year $0.46
  • Growth Rate Est. (year over year) +4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.21 +3.35%
on 08/05/26
27.66 -9.54%
on 08/04/26
-0.80 (-3.10%)
since 07/07/26
3-Month
21.92 +14.14%
on 05/20/26
27.66 -9.54%
on 08/04/26
+1.38 (+5.84%)
since 05/07/26
52-Week
18.80 +33.09%
on 01/20/26
27.66 -9.54%
on 08/04/26
+1.25 (+5.26%)
since 08/07/25

Most Recent Stories

More News
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 25.02 (-2.19%)
Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

—  A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis — — Exploratory clinical outcome...

PCRX : 25.02 (-2.19%)
Pacira: Q2 Earnings Snapshot

Pacira: Q2 Earnings Snapshot

PCRX : 25.02 (-2.19%)
Pacira BioSciences Reports Second Quarter 2026 Financial Results

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue...

PCRX : 25.02 (-2.19%)
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

- Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options - BRISBANE, Calif., July 28,...

PCRX : 25.02 (-2.19%)
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on...

PCRX : 25.02 (-2.19%)
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 25.02 (-2.19%)
PHARMACORP ANNOUNCES CLOSING OF C$11.5 MILLION BOUGHT DEAL PUBLIC OFFERING

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

PCRX : 25.02 (-2.19%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 25.02 (-2.19%)
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®

-- Expands Patient Access to Non-Opioid Postsurgical Pain Management  Across Outpatient Settings --  BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX),...

PCRX : 25.02 (-2.19%)

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 26.23
2nd Resistance Point 25.96
1st Resistance Point 25.49
Last Price 25.02
1st Support Level 24.74
2nd Support Level 24.47
3rd Support Level 24.00

See More

52-Week High 27.66
Last Price 25.02
Fibonacci 61.8% 24.28
Fibonacci 50% 23.23
Fibonacci 38.2% 22.18
52-Week Low 18.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.